title: [Which urologic treatment alternatives are there for the hemophiliac patient?].
abstract: OBJECTIVE
  Urological procedures are hazardous for hemophilic patients. The aim of this work is to report the treatment of 22 hemophilic patients in order to define prognosis factors and treatment options.
  
  
  METHODS
  22 patients have been treated: 8 had severe hemophilia, 5 A (FVIII < 1%), 3 B (F IX < 1%), 2 had moderate hemophilia A (FVIII 2 to 6%) and 10 minor hemophilia A (F VIII 7 to 30%). Two had acquired hemophilia with auto-anti-FVIII antibodies (ab). Four patients were HIV+. Eighteen patients were first referred to our hospital, and 3 were transferred from an other institution for persistent hematuria: one with anuria, one after bladder neck incision, and the other following suprapubic prostatectomy.
  
  
  RESULTS
  For patients without FVIII ab, a sufficient level of FVIII or IX (> 60%), could be achieved pre-operatively and maintained post operatively (4 to 20 days, according to the surgical procedure) by injections of FVIII, FIX or by injections of desmopressin. For one haemophilia A patient with anti-F VIII ab, transferred for uncontrollable bleeding after bladder neck incision, selective arterial embolization was successful. But for 2 patients with acquired haemophilia, improvement of the coagulation was insufficient, with human or porcine FVIII, activated prothombic complex concentrates or recombinant activated FVII. In spite of surgical procedures and arterial embolizations the 2 patients died.
  
  
  CONCLUSIONS
  The urological treatment of haemophilic patients needs to be performed in specialised centers. For patients without FVIII ab, classical urological procedures can be performed. But for patients with FVIII ab when alternative treatments (radiotherapy, LHRH agonists) can be used, the surgical procedures must be delayed; in emergency if hemostasis cannot be achieved arterial embolization could be useful.
authors.affiliation: Service d'Urologie, Hôpital de Bicêtre, Le Kremlin Bicêtre, France. www.uro.bicêtre.org
authors.forename: G
authors.initials: G
authors.lastname: Benoit
authors.forename: T
authors.initials: T
authors.lastname: Lambert
authors.forename: P
authors.initials: P
authors.lastname: Blanchet
authors.forename: Y
authors.initials: Y
authors.lastname: Laurian
authors.forename: P
authors.initials: P
authors.lastname: Lasjaunias
authors.forename: R
authors.initials: R
authors.lastname: D'Oiron
authors.forename: P
authors.initials: P
authors.lastname: Eschwege
authors.forename: J
authors.initials: J
authors.lastname: Langloys
authors.forename: S
authors.initials: S
authors.lastname: Droupy
authors.forename: F
authors.initials: F
authors.lastname: Kriaa
authors.forename: A
authors.initials: A
authors.lastname: Jardin
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D006467:Hemophilia A / Q000150:complications*; D006801:Humans; D008875:Middle Aged; D011379:Prognosis; D012720:Severity of Illness Index; D014570:Urologic Diseases / Q000150:complications* / Q000628:therapy*